Process for the preparation of apovincaminic acid ester derivatives
    11.
    发明授权
    Process for the preparation of apovincaminic acid ester derivatives 失效
    氨基丁酸酯衍生物的制备方法

    公开(公告)号:US4400514A

    公开(公告)日:1983-08-23

    申请号:US209265

    申请日:1980-11-21

    CPC分类号: C07D461/00

    摘要: The invention concerns a new process for the preparation of apovincaminic acid ester derivatives of the general formula (I) ##STR1## wherein R.sup.1 and R.sup.2 independently represent an alkyl group having 1 to 6 carbon atoms,and pharmaceutically acceptable salts thereof.According to the invention the apovincaminic acid ester derivatives of the general formula (I) are prepared by reacting the corresponding 9- and/or 10- and/or 11-halo-14-oxo-15-hydroxyimino-E-homo-eburnane derivatives with an alkanol of the general formula R.sup.1 --OH, wherein R.sup.1 is as defined above, and with a dehydrating concentrated acid, and subsequently reducing the 9- and/or 10- and/or 11-halo-apovincaminic acid esters obtained, selectively on the aromatic ring. Alternatively, the 9- and/or 10- and/or 11-halo-apovincaminic acid esters can also be used as starting materials. The invention includes the preparation of racemic and optically active apovincaminic acid ester derivatives and of their pharmaceutically acceptable salts, as well.

    摘要翻译: 本发明涉及一种制备通式(I)的氨基苯甲酸酯衍生物的新方法,其中R1和R2独立地表示具有1至6个碳原子的烷基,及其药学上可接受的盐。 根据本发明,通式(I)的氨基亚氨酸酯衍生物通过相应的9-和/或10-和/或11-卤代-14-氧代-15-羟基亚氨基-E-高 - 伊本恩衍生物 与通式R 1 -OH的烷醇,其中R 1如上定义,并与脱水浓酸反应,然后选择性地将所得的9-和/或10-和/或10-卤代 - 氨基丁酸酯还原 芳香环。 或者,9-和/或10-和/或11-卤代 - 氨基丁酸酯也可以用作原料。 本发明还包括外消旋和光学活性氨肽酸酯衍生物及其药学上可接受的盐的制备。

    10-halo-E-homoeburnane derivatives, a process for the preparation
thereof, a process for the use thereof as vasodilators, and
vasodilating compositions thereof
    12.
    发明授权
    10-halo-E-homoeburnane derivatives, a process for the preparation thereof, a process for the use thereof as vasodilators, and vasodilating compositions thereof 失效
    10-卤代-E-高聚乙二醇衍生物,其制备方法,其用作血管扩张剂的方法及其血管舒张组合物

    公开(公告)号:US4285950A

    公开(公告)日:1981-08-25

    申请号:US175383

    申请日:1980-08-05

    CPC分类号: C07D471/22 Y10S514/929

    摘要: The invention relates to new 10-halo-E-homoeburnane derivatives of the general formula (I), ##STR1## wherein R.sup.2 is a C.sub.1-6 alkyl group and X is halogen, and epimers, optically active derivatives and pharmaceutically acceptable acid addition salts thereof. These substances exert vasodilating effects and can be applied to advantage in the therapy.The new compounds are prepared so that a racemic or optically active 9-halo-octahydroindoloquinolisine derivative of the general formula (II), ##STR2## wherein R.sup.2 and X are as defined above and R.sup.1 is a C.sub.1-6 alkyl group, or an acid addition salt thereof is treated with a strong base, and, if desired, the 15-epimers of the resulting compound having the general formula (I) are separated from each other, and/or, if desired, the resulting substance is converted into its pharmaceutically acceptable acid addition salt and/or resolved.

    摘要翻译: 本发明涉及通式(I)的新的10-卤代 - 均 - 甲硼烷衍生物,其中R2是C1-6烷基且X是卤素的差向异构体,光学活性衍生物和药学上可接受的衍生物 其酸加成盐。 这些物质发挥血管扩张作用,可用于治疗中的优势。 制备新化合物,使得通式(II)的外消旋或光学活性的9-卤代 - 八氢吲哚-2-醇衍生物,其中R 2和X如上所定义,R 1是C 1-6烷基, 或其酸加成盐用强碱处理,如果需要,所得化合物的具有通式(I)的15-差向异构体彼此分离,和/或如果需要,所得物质为 转化成其药学上可接受的酸加成盐和/或分解。

    Hexahydroindoloquinolizinium and octahydroindoloquinolizine esters, and
method of increasing blood flow in an animal with hydroxyamino-eburnane
derivatives
    13.
    发明授权
    Hexahydroindoloquinolizinium and octahydroindoloquinolizine esters, and method of increasing blood flow in an animal with hydroxyamino-eburnane derivatives 失效
    六氢吲哚喹啉鎓和八氢二吲哚喹啉酯,以及用羟基氨基 - 伊本恩衍生物增加动物血流量的方法

    公开(公告)号:US4446139A

    公开(公告)日:1984-05-01

    申请号:US351506

    申请日:1982-02-23

    CPC分类号: C07D471/14 C07D461/00

    摘要: The invention relates to new hydroxyamino-eburnane derivatives of the general formula (I), ##STR1## wherein R.sup.1 and R.sup.2 each stand for a C.sub.1-6 alkyl group, as well as to pharmaceutically acceptable acid addition salts and optically active isomers of these compounds.These new compounds can be applied as peripheral vasodilatating agents or can be converted into other compounds, e.g. vincamine and apovincamine derivatives, of valuable therapeutical effects.The compounds of the general formula (I) are prepared according to the invention by reacting a hexahydro-indoloquinolisinium derivative of the general formula (II), ##STR2## wherein R.sup.2 is as defined above and X stands for an acid residue, with a methylenemalonic acid diester derivative of the general formula (III), ##STR3## wherein R.sup.1 is as defined above, subjecting the resulting product to catalytic hydrogenation, treating the resulting product with an alkali, and reacting the resulting octahydroindoloquinolisine monoester derivative with a nitrosating agent in an acidic medium.

    摘要翻译: 本发明涉及通式(I)的新型羟基氨基 - 伊本烷衍生物,其中R1和R2各自表示C1-6烷基,以及药学上可接受的酸加成盐和旋光异构体 的这些化合物。 这些新化合物可以作为外周血管舒张剂使用,也可以转化为其它化合物,例如 长春胺和氨肽素衍生物,具有宝贵的疗效。 通式(I)的化合物根据本发明通过使通式(II)的六氢 - 吲哚并喹啉鎓衍生物,其中R 2如上定义,X​​代表酸残基, 与通式(III)的亚甲基丙二酸二酯衍生物,其中R1如上所定义,使所得产物进行催化氢化,用碱处理所得产物,并使所得八氢二吲哚并喹啉酮单酯衍生物 在酸性介质中使用亚硝化剂。

    Process for preparation of cytostatic compounds
    14.
    发明授权
    Process for preparation of cytostatic compounds 失效
    细胞生长抑制化合物的制备方法

    公开(公告)号:US4410459A

    公开(公告)日:1983-10-18

    申请号:US293611

    申请日:1981-08-17

    CPC分类号: C07D519/04 Y10S514/908

    摘要: The invention relates to new cytostatic compound, process for their preparation and pharmaceutical compositions containing them. More particularly, there are provided new compounds of the general formula ##STR1## in which R.sup.4 is .beta.-hydroxyl andR.sup.3 is .alpha.-ethyl; orR.sup.4 is hydrogen andR.sup.3 is .beta.-ethyl;R" is a straight chained alkyl having from 1 to 10 carbon atoms, or a branched chained alkyl having from 3 to 10 carbon atoms, in which groups the carbon atom attached to the >N.sub.a -CH.sub.2 -O-- group has a primary or secondary configuration or an alkenyl or alkinyl having from 3 to 6 carbon atoms, or an aralkyl having from 1 to 3 carbon atoms in the alkyl moiety;R.sup.1 is methoxy andR.sup.2 is acetyl,provided that if R.sup.3 is .alpha.-ethyl and R.sup.4 .beta.-hydroxyl, R.sup.4 is other than ethyl.These compounds and N-desmethyl-N- ethoxy- methyl -vinblastine can be prepared according to the invention by transetherification of compounds of the compounds of the general formula ##STR2## with a large excess of alcohols of the general formulaR"--OH (III)Pharmaceutical compositions containing compounds of the general formula /I/ as active ingredients are also within the scope of invention.

    摘要翻译: 本发明涉及新的细胞生长抑制化合物,其制备方法和含有它们的药物组合物。 更具体地,提供了通式为(I)的新化合物,其中R 4是β-羟基并且R 3是α-乙基; 或R4是氢,R3是β-乙基; R“是具有1至10个碳原子的直链烷基或具有3至10个碳原子的支链烷基,其中与> Na-CH 2 -O-基团连接的碳原子具有伯或 二级构型或具有3至6个碳原子的烯基或炔基,或在烷基部分具有1至3个碳原子的芳烷基; R1是甲氧基,R2是乙酰基,条件是如果R3是α-乙基和R4β-羟基,R4不是乙基。 这些化合物和N-去甲基-N-乙氧基 - 甲基 - 长春花碱可以根据本发明通过将通式为“IMAGE”(II)的化合物的化合物与大量过量的通式R' '-OH(III)含有通式I I化合物作为活性成分的药物组合物也在本发明的范围内。

    N-Desmethyl-N-(allyloxymethyl)-vinblastine and antileukemic and
antilymphomic compositions and method of treatment
    15.
    发明授权
    N-Desmethyl-N-(allyloxymethyl)-vinblastine and antileukemic and antilymphomic compositions and method of treatment 失效
    N-去甲基-N-(烯丙氧基甲基) - 长春花碱和抗白血病和抗病毒组合物和治疗方法

    公开(公告)号:US4490378A

    公开(公告)日:1984-12-25

    申请号:US503791

    申请日:1983-06-13

    CPC分类号: C07D519/04 Y10S514/908

    摘要: The invention relates to new cytostatic compound, process for their preparation and pharmaceutical compositions containing them. More particularly, there are provided new compounds of the general formula ##STR1## in which R.sup.4 is .beta.-hydroxyl andR.sup.3 is .alpha.-ethyl; orR.sup.4 is hydrogen andR.sup.3 is .beta.-ethyl;R" is a straight chained alkyl having from 1 to 10 carbon atoms, or a branched chained alkyl having from 3 to 10 carbon atoms, in which groups the carbon atom attached to the >N.sub.a --CH.sub.2 --O-- group has a primary or secondary configuration or an alkenyl or alkinyl having from 3 to 6 carbon atoms, or an aralkyl having from 1 to 3 carbon atoms in the alkyl moiety;R.sup.1 is methoxy andR.sup.2 is acetyl, provided that if R.sup.3 is .alpha.-ethyl and R.sup.4 .beta.-hydroxyl,R.sup.4 is other than ethyl.These compounds and N-desmethyl-N-(ethoxymethyl)-vinblastine can be prepared according to the invention by transetherification of compounds of the compounds of the general formula ##STR2## with a large excess of alcohols of the general formulaR"--OH [III]Pharmaceutical compositions containing compounds of the general formula [I] as active ingredients are also within the scope of invention.

    摘要翻译: 本发明涉及新的细胞生长抑制化合物,其制备方法和含有它们的药物组合物。 更具体地,提供了通式为“IMAGE”/ I /的新化合物,其中R 4是β-羟基和R 3是α-乙基; 或R4是氢,R3是β-乙基; R“是具有1至10个碳原子的直链烷基或具有3至10个碳原子的支链烷基,其中与> Na-CH 2 -O-基团连接的碳原子具有伯或 二级构型或具有3至6个碳原子的烯基或炔基,或在烷基部分具有1至3个碳原子的芳烷基; R1是甲氧基,R2是乙酰基,条件是如果R3是α-乙基和R4β-羟基,R4不是乙基。 这些化合物和N-去甲基-N-(乙氧基甲基) - 长春花碱可以根据本发明通过将通式为“IMAGE”/ II /的化合物的化合物与大量过量的通式R' '-OH [III]含有通式[I]化合物作为活性成分的药物组合物也在本发明的范围内。

    Process for the isolation of alkaloid components from the plant Vinca
Rosea L.
    17.
    发明授权
    Process for the isolation of alkaloid components from the plant Vinca Rosea L. 失效
    从植物中分离生物碱成分的方法长春花

    公开(公告)号:US4172077A

    公开(公告)日:1979-10-23

    申请号:US908584

    申请日:1978-05-22

    CPC分类号: C07D519/04

    摘要: Tumor inhibiting alkaloids are recovered from Vinca Rosea L. by a method which comprises extracting the dried leaves with a solvent selected from the group consisting of an alkanol having 1 to 5 carbon atoms, a mixture of an alkanol having 1 to 5 carbon atoms and a dilute, aqueous solution, benzene and benzene homologs; subsequently purifying the alkaloid extract obtained by a phase-change method between immiscible solvents, precipitating the main amount of dimeric alkaloids in form of their sulphuric acid addition salts, isolating leurosine, vincistine, vinblastine, desacetoxy-vinblastine, N-desmethyl-vinblastine and desacetyl-vinblastine from the salt mixture obtained, and then completing the separation and isolation of the remaining alkaloids by separation and isolation by adjusting the pH-value of the mother liquor, after precipitation and removal of the salt mixture, to 5.5 to 10, extracting the solution with a water-immiscible organic solvent and separating vindoline, catharantine, 3',4' -anhydrovinblastine and leurosine from the extract by chromatography, extracting vindoline in the pH-range of 2.5 to 3.5 and catharantine 3',4'-anhydrovinblastine and leurosine in the pH-range of 5 to 6 with benzene or a benzene homologue, from the mother liquor obtained when isolating the salt mixture, and separating a mixture of leurosine and 3',4'-anhydrovinblastine by crystallization, epoxidizing this mixture with an oxygen source, or separating the mixture into its components by chromatography, and subsequently epoxidizing the 3',4'-anhydrovinblastine component to leurosine, and isolating catharantine remaining from the mother liquor obtained when separating the crystalline mixture, or separating the extract containing catharantine, 3',4'-anhydrovinblastine and leurosine into its components by chromatography.

    摘要翻译: 通过包括用选自具有1至5个碳原子的链烷醇,具有1至5个碳原子的链烷醇和1至5个碳原子的链烷醇的溶剂萃取干燥叶子的方法从长春花(Vinca Rosea L.)回收肿瘤抑制生物碱 稀释水溶液,苯和苯同系物; 随后将不相溶溶剂之间的相变法获得的生物碱提取物纯化,以其硫酸加成盐的形式沉淀出主要量的二聚生物碱,分离出白蛋白,长春新碱,长春花碱,去乙酰氧基 - 长春花碱,N-去甲基长春花碱和去乙酰基 从所得的盐混合物中分离并分离残留的生物碱,然后通过调节沉淀和除去盐混合物后的pH值,分离和分离,得到5.5〜10 溶液与水不混溶的有机溶剂混合,并通过色谱法从提取物中分离出vindoline,catharantine,3',4'-脱氢长春花碱和leurosine,在2.5至3.5的pH范围内提取vindoline,并检测3',4'-脱氢长春花碱和 柠檬酸在5〜6的pH范围内用苯或苯同系物,从分离盐混合物时得到的母液,和sepa 通过结晶评估白蛋白和3',4'-脱氢长春花碱的混合物,用氧源将该混合物环氧化,或通过色谱法将该混合物分离成其组分,随后将3',4'-脱氢长春花碱组分环氧化成亮氨酸,以及 隔离离开结晶混合物时获得的母液中残留的检疫物,或通过色谱法将含有检疫胺,3',4'-脱氢长春花碱和酪氨酸的提取物分离成其组分。